Transitional epithelium

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, August 11, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Nausea, Trial of the century, Female, SEC, Cancer, Clinical trial, Urine, Pain, Blood, Fever, Patient, Swelling, Skin, Clothing, Sodium bicarbonate, Perforation, Breast milk, Disease, Risk, NDA, Technology, Private Securities Litigation Reform Act, UTUC, Patient Information Advisory Group, Recurrence, Ureter, Safety, Water, Birth, Growth, Neoplasm, Man, Fatigue, NMIBC, Bladder cancer, Bone marrow, COVID-19, Stomach, Urinary bladder, Urination, Kidney, Time, Orphan drug, Transitional cell carcinoma, FDA, Vomiting, Abdomen, Nephrectomy, Company, Twitter, View, TURBT, Urinary tract infection, Transitional epithelium, Medicine, Adult, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Pharmakon—Danish College of Pharmacy Practice, Mitomycin C, Mitomycins

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005112/en/

UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Tuesday, May 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ureter, Birth, Swelling, Kidney, Safety, Urination, Patient Information Advisory Group, Risk, Skin, Female, NMIBC, View, SEC, Trial of the century, Technology, Nausea, Stomach, Pain, Twitter, Water, Perforation, Company, Probability, Patient, Urine, Clinical trial, FDA, Nephrectomy, Sodium bicarbonate, Vomiting, Private Securities Litigation Reform Act, Bone marrow, Medicine, Neoplasm, NDA, Time, Fatigue, UTUC, Clothing, Growth, Man, COVID-19, Transitional cell carcinoma, Abdomen, Fever, Cancer, Blood, Orphan drug, Urinary bladder, Urinary tract infection, Adult, Breast milk, Transitional epithelium, Recurrence, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Mitomycins, Mitomycin C, Pharmakon—Danish College of Pharmacy Practice

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005510/en/

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

Retrieved on: 
Tuesday, April 5, 2022
Software, Networks, Internet, Hardware, Pharmaceutical, Electronic Design Automation, Data Management, Oncology, Consumer Electronics, Technology, Biotechnology, Health, Telecommunications, Risk, Recurrence, LinkedIn, Diagnosis, Agilent Technologies, NYSE, Cancer, Death, Marie Cassidy, Quality of life, Software, Squamous cell carcinoma, Transitional cell carcinoma, Twitter, Hope, Matthew 28:8, Physician, Union, Nivolumab, Solution, News, Bristol Myers Squibb, PD-L1, Transitional epithelium, Patient, Disease, Palladium, EU, Facebook

The expanded use of PD-L1 IHC 28-8 pharmDx helps physicians in the EU identify MIUC patients for adjuvant treatment with OPDIVO.

Key Points: 
  • The expanded use of PD-L1 IHC 28-8 pharmDx helps physicians in the EU identify MIUC patients for adjuvant treatment with OPDIVO.
  • Agilent supports pathologists with products that provide accuracy and reliability in PD-L1 testing, said Sam Raha, president of Agilent's Diagnostics and Genomics Group.
  • We are pleased that this now includes the treatment of MIUC for adjuvant treatment with OPDIVO.
  • Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma.

UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, March 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Private Securities Litigation Reform Act, Risk, Adult, Fatigue, SEC, Urination, Cancer, Medicine, Neoplasm, Breast milk, Sodium bicarbonate, Technology, Twitter, UTUC, Patient Information Advisory Group, Trial of the century, Time, NDA, Ureter, Urine, Recurrence, Transitional cell carcinoma, Kidney, Nausea, Pain, View, Clothing, Perforation, Swelling, Female, Nephrectomy, Vomiting, NMIBC, Clinical trial, Growth, Urinary tract infection, Man, Urinary bladder, FDA, Patient, Birth, Abdomen, Company, Stomach, ATLAS, Skin, Bone marrow, Fever, Safety, Orphan drug, COVID-19, Arm, Transitional epithelium, Blood, TURBT, Water, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Mitomycin C, Mitomycins, JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ENVISION TRIAL, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ENVISION TRIAL, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005260/en/

Seagen Canada Announces Availability of PADCEV® to Treat Advanced Bladder Cancer

Retrieved on: 
Tuesday, January 25, 2022
People, National Cancer Institute, Government of Canada, Survival, American Society of Clinical Oncology, Trial of the century, Patient, MMAE, Squamous cell carcinoma, Man, Transitional epithelium, Apoptosis, Union, General manager, Bladder cancer, Metastasis, Veni, vidi, vici, Disease, Society, Brentuximab vedotin, Cancer, Seagen, Recurrence, EV, Tissue, Occupation, Risk factor, Smoking, Princess Margaret Cancer Centre, Prognosis, O'Donnell dynasty, ADC, Diagnosis, Quality of life, Pivotal trial, Induced cell cycle arrest, Risk, Transitional cell carcinoma, Twitter, Professor, Cell, Platinum, Enfortumab vedotin, Medical imaging, Dietary supplement, Pharmaceutical industry, Immunotherapy, MD

A recent Seagen Canada survey gauging Canadian's knowledge of bladder cancer, conducted by Leger Research, found that many Canadians have limited knowledge as it relates to the condition.

Key Points: 
  • A recent Seagen Canada survey gauging Canadian's knowledge of bladder cancer, conducted by Leger Research, found that many Canadians have limited knowledge as it relates to the condition.
  • "Seagen is proud of our transformative scientific discoveries that continue to address and support those who live with cancer," says Sandra Heller, General Manager of Seagen Canada Inc. "PADCEV represents our dedication to improving the lives of patients through innovative targeted therapies."
  • Bladder Cancer.
  • Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer.

UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, November 15, 2021
Biotechnology, Pharmaceutical, Health, TURBT, Urine, Bone marrow, Cancer, Female, Clinical trial, Swelling, Nephrectomy, Growth, COVID-19, Urinary tract infection, Perforation, Pain, Solution, Transitional epithelium, ATLAS, Safety, Abdomen, Kidney, Recurrence, Patient Information Advisory Group, Technology, Blood, Transitional cell carcinoma, Probability, Ureter, Vomiting, Fever, Fatigue, Clothing, Patient, FDA, Adult, Bladder cancer, View, Private Securities Litigation Reform Act, Medicine, Orphan drug, Breast milk, Risk, Twitter, UTUC, Urinary bladder, SEC, Urination, Man, Nausea, Sodium bicarbonate, Arm, Water, Birth, Stomach, Neoplasm, Company, Skin, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UGN-102, the Phase 3 ATLAS Trial, UroGen Pharma Ltd., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005427/en/

Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Retrieved on: 
Friday, October 1, 2021
Squamous cell carcinoma, SITC, ERK5, 2021 Essex County Council election, Nivolumab, Society for Immunotherapy of Cancer, Conference, Cancer, Annual general meeting, LinkedIn, Immunology, Twitter, Program, Immunotherapy, Bristol Myers Squibb, Aryl hydrocarbon receptor, TEAD, KRAS, Transitional epithelium, Tumor microenvironment, Hippopotamus, AHR, Society, GLOBE, Pharmaceutical industry

IK-175 is an oral AHR antagonist designed to modulate the tumor microenvironment to increase both innate and adaptive immunity and is currently being studied in a Phase 1 clinical trial .

Key Points: 
  • IK-175 is an oral AHR antagonist designed to modulate the tumor microenvironment to increase both innate and adaptive immunity and is currently being studied in a Phase 1 clinical trial .
  • Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021) is being held in-person and virtually November 10-14, 2021.
  • For more information on the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and how to register, visit the website .
  • Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.

Lucence Presents Data at ESMO 2021 Showing Liquid Biopsy Detects Actionable Genomic Alterations in Bladder Cancer Patients Undergoing Immunotherapy

Retrieved on: 
Monday, September 13, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology

Precision oncology company Lucence, in collaboration with researchers at Dana-Farber Cancer Institute and Brigham and Womens Hospital, is sharing data highlighting the capabilities of its amplicon-based liquid biopsy technology to detect and characterize genomic alterations in ctDNA in patients with late-stage bladder cancer undergoing immunotherapy.

Key Points: 
  • Precision oncology company Lucence, in collaboration with researchers at Dana-Farber Cancer Institute and Brigham and Womens Hospital, is sharing data highlighting the capabilities of its amplicon-based liquid biopsy technology to detect and characterize genomic alterations in ctDNA in patients with late-stage bladder cancer undergoing immunotherapy.
  • The data will be presented as part of a virtual poster presentation at the European Society for Medical Oncology (ESMO) Congress 2021.
  • Most mUC patients do not respond, or develop resistance to, ICI and obtaining tissue biopsies before and throughout treatment is invasive and presents risks of complications.
  • Lucence makes ultrasensitive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment.

Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Urothelial Cancer

Retrieved on: 
Thursday, August 5, 2021
MD, Society for Immunotherapy of Cancer, Society, Research, SITC, CPG, Maintenance, Journal, Squamous cell carcinoma, Science, Publication, Immunotherapy, YouTube, Patient, Transitional cell carcinoma, Transitional epithelium, Twitter, Toxicity, Quality of life, Urethra, Joint Interoperability Test Command, Ira Pastan, Survival, Report, LinkedIn, Facebook, Medical imaging, Pharmaceutical industry

Urothelial cancer represents a significant public health concern, as the sixth most common type of cancer in the United States.

Key Points: 
  • Urothelial cancer represents a significant public health concern, as the sixth most common type of cancer in the United States.
  • "Immunotherapy fills an important unmet need for patients with urothelial cancer who are too frail or are unwilling to endure the toxicity associated with chemotherapy," said Matthew D. Galsky, co-chair of the SITC Urothelial Cancer Immunotherapy Guideline Expert Panel.
  • Published in the Journal for ImmunoTherapy of Cancer (JITC) , SITC's open access, peer-reviewed online journal, " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer ," contains evidence- and consensus-based recommendations developed by a panel of experts to assist healthcare professionals on the important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs) and patient quality of life (QOL) considerations.
  • "The treatment landscape for urothelial cancer is evolving and this new clinical practice guideline will be a valuable resource for the oncology community," said SITC President Patrick Hwu, MD.

 UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Chemical compounds, Health sciences, Organic compounds, Orphan drugs, Breakthrough therapy, Aziridines, Cancer treatments, Mitomycin C, Oncology, Fast track, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UGN-102, the Phase 3 ATLAS Trial, UroGen Pharma Ltd., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005328/en/